Mandate

Vinge advises EQT in connection with sale of care giant Aleris

July 02, 2010

EQT III has entered into an agreement to sell the Aleris healthcare group to Investor AB. The transaction value is SEK 4.4 billion with a supplementary purchase price of up to SEK 100 million. The transaction is subject to approval by the relevant competition authorities.

The Vinge team advising EQT consisted of Tuula Tallavaara, David Andersson, Johan Mattsson and Ulrich Ziche. Peter Alstergren provided competition law advice and Carl Gustav De Geer was the responsible partner.

Aleris has approximately 5000 employees and has operations in Sweden, Norway and Denmark. Aleris’ turnover in 2009 was approximately SEK 4 billion.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026